Loring Wolcott & Coolidge Fiduciary Advisors LLP Arbutus Biopharma Corp Call Options Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $10.3 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ABUS
# of Institutions
169Shares Held
103MCall Options Held
649KPut Options Held
666K-
Morgan Stanley New York, NY22.6MShares$79.3 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.2MShares$46.5 Million22.74% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$40.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.95MShares$31.4 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.74MShares$30.7 Million4.68% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $526M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...